No concomitant treatment of strong CYPA inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. Johns wort)
CYPA Inducers: patients chronically receiving drugs that are known potent CYPA inducers within  days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifampin, and St. Johns wort are not eligible (with the exception of glucocorticoids)
Patients cannot be on systemic treatment with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use Ginkgo biloba or St. Johns wort within  days of registration
CYPA inducers: patients chronically receiving drugs that are known potent CYPA inducers within  days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, ritonavir, and St. Johns wort are not eligible; the topical use of these medications (if applicable) is allowed
Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns wort) or moderate CYPA inducers (eg. bosentan, efavirenz, modafinil); the required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns wort) or moderate CYPA inducers (e.g., bosentan, efavirenz, modafinil); the required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents
Concomitant use of strong CYPA inducers such as rifampicin, phenytoin, carbamazepine, phenobarbital or St. Johns wort as these may significantly reduce the availability of exemestane
Systemic treatment, within  days before the first dose of ixazomib with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Systemic treatment, within  days before the first dose of ixazomib, with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. Johns wort
Systemic treatment with strong CYPA inducers (e.g. rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, gingko biloba, St. Johns wort) within  days before registration
Systemic treatment with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, Gingko biloba, St. Johns wort) =<  days prior to registration
Concomitant use of known strong CYPA inducers (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns Wort) or moderate CYPA inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents
Systemic treatment with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. Johns wort ?  days prior to registration
Patients receiving concomitant strong CYPA inducers (avasimibe, carbamazepine, phenytoin, rifampin, rifabutin, St. Johns wort) within  days of start of study therapy.
Current use or anticipated need for drugs that are known strong CYPA/ inducers, including their administration within  days prior to patient randomization, eg,\r\nphenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentin, clevidipine, St Johns wort
Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns wort) or moderate CYPA inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents.
Subjects who have used strong CYPA inducers (eg, phenytoin, carbamazepine, phenobarbital, St. Johns wort [hypericum perforatum], dexamethasone at a dose of greater than  mg daily, or rifampin [rifampicin], and/or rifabutin) within  days before first dose of study treatment
The subject requires chronic concomitant treatment with strong CYPA inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. Johns wort)
Systemic treatment, within  days before the first dose of and dexamethasone (DId), with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Current use or anticipated need for drugs that are known strong or moderate CYPA inducers including their administration within  weeks prior to the first study treatment (ie, phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentin, clevidipine, St. Johns wort); for participants in the dose escalation portion, no CYPA inducers should be administered during the first  days of the study, regardless of strength
Systemic treatment with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use of Ginkgo biloba or St. Johns wort =<  days prior to registration
Current use or anticipated inability to avoid use of drugs that are known strong CYPA/ inducers (carbamazepine, dexamethasone, fosphenytoin, phenytoin, phenobarbital, rifabutin, rifampin, rifapentine, St. Johns wort)
Systemic treatment with strong cytochrome P- A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use of St. John's wort within  days before randomization.
Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns Wort) or moderate CYPA inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents
Concomitant use of known strong CYPA inducers (e.g. phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns Wort) or moderate CYPA inducers (e.g. bosentan, efavirenz, modafinil); the required washout period prior to starting olaparib is  weeks for phenobarbital and  weeks for other agents
Systemic treatment with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, St. Johns wort) =<  days prior to registration
Concomitant use of strong CYPA inducers (e.g., phenytoin, rifampicin, carbamazepine, St. Johns wort) and moderate CYPA inducers (e.g., bosentan, efavirenz, etravirine, modafinil, nafcillin)
Systemic treatment with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. Johns wort =<  days prior to registration
Systemic treatment, within  days before the beginning of protocol therapy, with CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. Johns wort
Current use or anticipated inability to avoid use of drugs that are known strong CYPA/ inducers (carbamazepine, dexamethasone, fosphenytoin, phenytoin, phenobarbital, rifabutin, rifampin, rifapentine, St. Johns wort)
Strong CYPA inducers, including: phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort
Systemic treatment, within  days before the first dose of ixazomib, with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. Johns wort
Anticipated need for treatment with drugs that are known CYPA or CYPA inducers (i.e. carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, and St. Johns wort)
Are receiving systemic treatment with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's wort) within  days before randomization.
Systemic treatment, within  days before the first dose of ixazomib, with strong cytochrome P A (CYPA) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.
Concomitant use of known strong (e.g. phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns Wort) or moderate CYPA inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is  weeks for phenobarbital and  weeks for other agents.
Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns wort) or moderate CYPA inducers (eg. bosentan, efavirenz, modafinil); the required washout period prior to starting olaparib is  weeks for enzalutamide,  weeks for phenobarbital and  weeks for other agents
Systemic treatment, ?  days before registration, with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or St. Johns wort
Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns wort) or moderate CYPA inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents.
Concurrent use of strong CYPA/ inducers such as carbamazepine, phenytoin, rifampin, and St. Johns wort are prohibited
Concurrent treatment with strong CYPA inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital)
The subject requires chronic concomitant treatment of strong CYPA inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. Johns wort)
Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns wort) or moderate CYPA inducers (e.g. bosentan, efavirenz, modafinil); the required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents
Current use or anticipated need for treatment with drugs that are known strong CYPA/ inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. Johns wort
Receiving any medications or substances that are inducers of CYP A; use of the following inducers is prohibited =<  days prior to registration:\r\n* Inducers of CYPA: efavirenz, nevirapine, carbamazepine, modafinil, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. Johns wort
Concurrent medications which strongly inhibit or induce cytochrome P (CYP) enzymes (gemfibrozil, rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, bosentan, efavirenz, etravirine, modafinil, nafcillin, St. Johns Wort)
Patients chronically receiving drugs that are known strong CYPA/ inducers within  days prior to study enrollment, including but not limited to rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, and St Johns Wort are not eligible
Patients chronically receiving drugs that are known potent CYPA inducers within  days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, tipranavir, ritonavir, and St. Johns wort are not eligible; the topical use of these medications (if applicable) is allowed
Receiving any medications or substances that are inducers of CYPA (efavirenz, nevirapine, carbamazepine, modafinil, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. Johns wort); use of the aforementioned inducers is prohibited =<  days prior to registration
Patients chronically receiving drugs that are known potent CYPA inducers within  days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, tipranavir, ritonavir, and St. Johns wort are not eligible; the topical use of these medications (if applicable) is allowed
Systemic treatment with strong CYPA inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within  days before the first dose of study treatment.
Has current use (within  days of randomization) or anticipated need for treatment with drugs that are known strong CYPA/ inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort; or drugs that are known with proarrhythmic potential.
Taking any of the following: Rifampicin, St. John's Wort, phenytoin, carbamazepine, phenobarbital, dexamethasone
Avoid the use of concomitant strong CYPA/PgP inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, and phenobarbital).
Unable or unwilling to discontinue use of ketoconazole or St Johns wort; use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated; if patients require phenytoin, carbamazepine or phenobarbital monitoring of drug levels is suggested during the study
Receiving any medications or substances that are inducers of CYPA; use of the following inducers are prohibited =<  days prior to registration\r\n* Strong inducers of CYPA/; > % decrease in AUC\r\n** Avasimibe\r\n** Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Rifampin (Rifadin)\r\n** St. Johns wort\r\n** Mitotane\r\n** Rifabutin\r\n** Phenobarbital\r\n* Moderate inducers of CYPA/; -% decrease in AUC\r\n** Bosentan (Tracleer)\r\n** Efavirenz (Sustiva)\r\n** Etravirine (Intelence)\r\n** Modafinil (Provigil)\r\n** Nafcillin\r\n** Genistein\r\n** Ritonavir\r\n** Talyiraline\r\n** Thioridazine\r\n** Tipranavir\r\n** Nevirapine (Viramune)\r\n** Phenobarbital (Luminal)\r\n** Rifabutin (Mycobutin)\r\n** Troglitazone
Received potent CYPA inducers (such as rifampin, carbamazepine, phenytoin, St. Johns wort) within  days prior to the first dose of study treatment
Participant has received the following within  days prior to the initiation of study treatment: strong and moderate CYPA inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.
Current use or anticipated need for treatment with drugs that are known CYPA or CYPA inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, and St. Johns wort)
Concomitant use of known strong CYPA inducers (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St Johns wort) or moderate CYPA inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents.
Patients cannot receive CYPA inducing anticonvulsants including carbamazepine, felbamate, phenobarbital, phenytoin, primidone and oxcarbazepine, or other CYPA inducers such as St. Johns wort
Receiving any medications or substances that are inducers of CYPA; use of the following inducers are prohibited =<  days prior to registration; concurrent use is not allowed simultaneously with nilotinib during the study\r\n* Strong inducers of CYPA/ > % decrease in AUC\r\n** Avasimibe\r\n** Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Rifampin (Rifadin)\r\n** St. Johns wort\r\n* Moderate inducers of CYPA/ -% decrease in AUC\r\n** Bosentan (Tracleer)\r\n** Efavirenz (Sustiva)\r\n** Etravirine (Intelence)\r\n** Modafinil (Provigil)\r\n** Nafcillin\r\n** Nevirapine (Viramune)\r\n** Phenobarbital (Luminal)\r\n** Rifabutin (Mycobutin)\r\n** Troglitazone
Concurrent use of drugs that are known CYPA inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. Johns wort
Receiving any medications or substances that are strong or moderate inducers of CYPA; use of the following inducers are prohibited =<  days prior to randomization: efavirenz (Sustiva), nevirapine (Viramune), carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR), modafinil (Provigil), phenobarbital (Luminal), phenytoin (Dilantin, Phenytek), pioglitazone (Actos), rifabutin (Mycobutin), rifampin (Rifadin), St. Johns wort
Treatment with strong CYPA inducers: \r\n* Anticonvulsants: phenytoin, carbamazepine, Phenobarbital, oxcarbazepine; \r\n* Human immunodeficiency virus (HIV) antiretrovirals: efavirenz, nevirapine; \r\n* Antibiotics: rifampin (rifampicin), rifabutin, rifapentine; \r\n* Miscellaneous: St. John's Wort, modafinil, pioglitazone, troglitazone
EXPANSION COHORT ONLY: Treatment with strong CYPA inducers: \r\n* Anticonvulsants: phenytoin, carbamazepine, Phenobarbital, oxcarbazepine; \r\n* Human immunodeficiency virus (HIV) antiretrovirals: efavirenz, nevirapine; \r\n* Antibiotics: rifampin (rifampicin), rifabutin, rifapentine; \r\n* Miscellaneous: St. John's Wort, modafinil, pioglitazone, troglitazone
Concomitant use of phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital or St. Johns wort, cyclosporine, diltiazem, ketoconazole should be discontinued if possible
Patients taking phenytoin, carbamazepine, and Phenobarbital
Subjects who have used strong cytochrome CYPA inducers (e.g., phenytoin, carbamazepine, phenobarbital, St. John's wort [Hypericum perforatum], dexamethasone at a dose of greater than  mg daily for more than one day, or rifampin [rifampicin], and/or rifabutin) within  days before randomization
Using and unable to discontinue use of concomitant strong CYPA inducers (e.g., including but not limited to St. John's Wort, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital)
Concomitant use of phenytoin, carbamazepine, rifampicin, phenobarbital, or St John's Wort or CYPA (e.g. itraconazole, ketoconazole)
Use of the following inducers are prohibited =<  days prior to registration\r\n* Avasimibe\r\n* Bosentan (Tracleer)\r\n* Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n* Efavirenz (Sustiva)\r\n* Modafinil (Provigil)\r\n* Phenobarbital (Luminal)\r\n* Phenytoin (Dilantin, Phenytek)\r\n* Rifabutin (Mycobutin)\r\n* Rifampin (Rifadin)\r\n* St. Johns wort
Patients who need to take CYPA inducers, such as phenobarbital, dexamethasone, carbamazepine, phenytoin, rifampicin, or non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, nevirapine, etravirine) will be excluded; prior use of these agents is acceptable, as long as they are stopped at least a week prior to study entry
Receiving any medications or substances that are inducers of CYPA; use of the following inducers are prohibited =<  days prior to registration\r\n* Inducers of CYPA \r\n** Efavirenz (Sustiva)\r\n** Nevirapine (Viramune)\r\n** Carbamazepine (Carbatro, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n** Modafinil (Provigil)\r\n** Phenobarbital (Luminal)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Pioglitazone (Acto)\r\n** Rifabutin (Mycobutin)\r\n** Rifampin (Rifadin)\r\n** St. Johns wort
On scheduled potent CYPA inducers at the time of study enrollment (avasimibe, carbamazepine, phenytoin, rifampin, efavirenz, nevirapine, barbiturates, glucocorticoids, modafinil, oxcarbazine, phenobarbital, pioglitazone, rifabutin, St. Johns wort, troglitazone)
Received one or more of the following drugs within  days prior to starting study: rifampin, rifabutin, carbamazepine, phenytoin, nevirapine, long-acting barbiturates
Use of the following CYPA inducers: rifampin, rifabutin, carbamazepine, efavirenz, phenobarbital, phenytoin, fosphenytoin, primidone, and St. Johns wort)
Use of potent CYPA inducers, including but not limited to rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's wort
Concomitant use of CYPA inducer medication (rifampicin, phenytoin, carbamazepine, phenobarbital, and St. Johns wort)
Use of CYPA inducers such as rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's wort
Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. Johns wort) of CYPA function
Current use or anticipated need for drugs that are known strong and moderate CYPA inducers, including their administration within  days prior to the first PF- dose (i.e., phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, clevidipine, St. Johns wort)
Use of drugs that are known strong CYPA inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort.
strong CYPA inducers (including, but not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St. John's Wort)
